Search

Your search keyword '"Bellotti V"' showing total 413 results

Search Constraints

Start Over You searched for: Author "Bellotti V" Remove constraint Author: "Bellotti V"
413 results on '"Bellotti V"'

Search Results

201. Reconstruction of nonrepairable acetabular labral tears with allografts: mid-term results.

202. Mini-open approach for femoroacetabular impingement: 10 years experience and evolved indications.

203. Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue Targeting.

204. Rational design of mutations that change the aggregation rate of a protein while maintaining its native structure and stability.

205. D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile.

206. Amyloid persistence in decellularized liver: biochemical and histopathological characterization.

207. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis.

208. Bifunctional crosslinking ligands for transthyretin.

209. Systemic amyloidosis: lessons from β2-microglobulin.

210. Probing the influence of citrate-capped gold nanoparticles on an amyloidogenic protein.

211. The H50Q mutation induces a 10-fold decrease in the solubility of α-synuclein.

212. Enhanced toxicity of silver nanoparticles in transgenic Caenorhabditis elegans expressing amyloidogenic proteins.

213. Hip resurfacing arthroplasty: mid-term results in 486 cases and current indication in our institution.

214. Rapid proton-detected NMR assignment for proteins with fast magic angle spinning.

215. Radiographic findings of femoroacetabular impingement in capoeira players.

216. Assessment of cellular responses after short- and long-term exposure to silver nanoparticles in human neuroblastoma (SH-SY5Y) and astrocytoma (D384) cells.

217. Class I major histocompatibility complex, the trojan horse for secretion of amyloidogenic β2-microglobulin.

218. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.

219. Reduction of conformational mobility and aggregation in W60G β2-microglobulin: assessment by 15N NMR relaxation.

220. Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin.

221. Structure of an early native-like intermediate of β2-microglobulin amyloidogenesis.

222. Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis.

223. Monitoring the interaction between β2-microglobulin and the molecular chaperone αB-crystallin by NMR and mass spectrometry: αB-crystallin dissociates β2-microglobulin oligomers.

224. Risk factors for dislocation arthropathy after Latarjet procedure: a long-term study.

225. Fibrillogenesis of human β2 -microglobulin in three-dimensional silicon microstructures.

226. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin.

227. Single-shot NMR measurement of protein unfolding landscapes.

228. Determining the energy landscape of proteins by a fast isotope exchange NMR approach.

229. A recurrent D-strand association interface is observed in β-2 microglobulin oligomers.

230. Pathological self-aggregation of β(2)-microglobulin: a challenge for protein biophysics.

231. C. elegans expressing human β2-microglobulin: a novel model for studying the relationship between the molecular assembly and the toxic phenotype.

232. D-strand perturbation and amyloid propensity in beta-2 microglobulin.

233. The effects of an ideal beta-turn on beta-2 microglobulin fold stability.

234. Enhanced molecular chaperone activity of the small heat-shock protein alphaB-cystallin following covalent immobilization onto a solid-phase support.

235. Molecular dynamics simulation of β₂-microglobulin in denaturing and stabilizing conditions.

236. Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta2-microglobulin variant.

237. Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils.

238. The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease.

239. Trapping of palindromic ligands within native transthyretin prevents amyloid formation.

240. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

241. Embryonic stem and haematopoietic progenitor cells resist to Aβ oligomer toxicity and maintain the differentiation potency in culture.

242. Folding and fibrillogenesis: clues from beta2-microglobulin.

243. DE-loop mutations affect beta2 microglobulin stability, oligomerization, and the low-pH unfolded form.

244. Fibrillar vs crystalline full-length beta-2-microglobulin studied by high-resolution solid-state NMR spectroscopy.

245. Native-unlike long-lived intermediates along the folding pathway of the amyloidogenic protein beta2-microglobulin revealed by real-time two-dimensional NMR.

246. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview.

247. Doxorubicin and congo red effectiveness on prion infectivity in golden Syrian hamster.

248. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

249. beta2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity.

250. Human beta-2 microglobulin W60V mutant structure: Implications for stability and amyloid aggregation.

Catalog

Books, media, physical & digital resources